Repligen Likely to Benefit From Diverse Growth Factors, RBC Says
Repligen (RGEN) is expected to benefit from diverse growth drivers in a strengthening bioprocessing market, RBC Capital Markets said in a Thursday note."Bioprocessing demand trends are the most robust in Tools, and Repligen is a pure play," the note said.The report also pointed to growth prospects at its commercial products, biosimilars, product replacement cycles, and a strategyreboot in China.The note said the growth drivers should enable the firm to return to mid-teens organic sales growth, as RBC resumes coverage of Repligen with an outperform rating and a $160 price target."The growth pressures associated with a specific gene therapy customer should lap next year, while several tailwinds...should ramp," the report said.Price: $105.97, Change: $+2.59, Percent Change: +2.50%
